Home / Formulary / Semaglutide

Back to formulary

LORIUM · 5 mg LYOPHILISED VIAL

Third-party tested · COA included with every lot

Metabolic ● In stockPrescription required

Semaglutide

Name: Semaglutide
Brand: LORIUM
SKU: semaglutide
Availability: InStock

GLP-1 receptor agonist · GLP-1 S

GLP-1 S is a premium, long-acting GLP-1 receptor agonist engineered with 94% homology to natural human GLP-1. Structurally optimized to resist enzymatic degradation, it delivers sustained metabolic control, profound appetite suppression, and comprehensive multi-organ protection.

$229 / month · 5 mg

Request through a provider Start intake to prescribe

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. It is dispensed only pursuant to a valid prescription following evaluation by a licensed provider.

Researched effects

Effects observed in the cited literature. Individual results are not guaranteed. Statements have not been evaluated by the FDA.

Glycemic Precision

Reduces HbA1c by 1.5%–2.2%; up to 70% achieve an HbA1c < 7%.

Weight Optimization

Mean 15.2% weight loss, with 40% achieving a ≥ 20% reduction.

Cardiovascular Defense

Driven by a 26% reduction in major cardiovascular events.

Extended Half-Life

~165 hours of continuous metabolic support.

Smart Release

Stimulates insulin only when glucose levels rise.

Sustained Efficacy

Studied weight and glycemic control maintained for up to 2 years.

Multi-Organ Protection

Delivers systemic benefits for kidney, liver, and neurological health.

Specifications

ClassGLP-1 receptor agonist

CAS number910463-68-2

Molar mass4113.6 g/mol

Available sizes5 mg, 10 mg

AdministrationOnce-weekly subcutaneous dosing protocol.

CategoryMetabolic

View a sample certificate of analysis →

Clinical references

Davies, M., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet, 397(10278), 971-984. DOI: 10.1016/S0140-6736(21)00213-0
Garvey, W.T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. DOI: 10.1038/s41591-022-02026-4
Marso, S.P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM, 375(19), 1834-1844. DOI: 10.1056/NEJMoa1607141
Nauck, M.A., et al. (2019). Semaglutide vs dulaglutide once weekly (SUSTAIN 7). Lancet Diabetes & Endocrinology, 7(10), 776-785. DOI: 10.1016/S2213-8587(19)30224-X
Rubino, D., et al. (2021). Continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 325(14), 1414-1425. DOI: 10.1001/jama.2021.3224